US 11,744,873 B2
Compositions and methods for the treatment of metabolic and liver disorders
Brian Lian, Rancho Santa Fe, CA (US); Geoffrey E. Barker, Carlsbad, CA (US); Maureen Barnes, San Diego, CA (US); Kader Yagiz, San Diego, CA (US); and Erland Stevens, Davidson, NC (US)
Assigned to Viking Therapeutics, Inc., San Diego, CA (US)
Filed by Viking Therapeutics, Inc., San Diego, CA (US)
Filed on Nov. 18, 2022, as Appl. No. 17/990,629.
Application 17/990,629 is a continuation of application No. PCT/US2022/012807, filed on Jan. 18, 2022.
Claims priority of provisional application 63/139,676, filed on Jan. 20, 2021.
Prior Publication US 2023/0105647 A1, Apr. 6, 2023
Int. Cl. A61K 38/16 (2006.01); A61P 43/00 (2006.01)
CPC A61K 38/16 (2013.01) [A61P 43/00 (2018.01)] 25 Claims
 
1. A compound having the structure of formula I-a, I-b, or I-c:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
X and Y each are independently selected from the group consisting of —OR4, NR5R6, C1-6 alkyl and haloC1-6 alkyl;
each R4 is independently selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C6-10 aryloxy and C6-10 aryl alkoxy;
each R5 is independently hydrogen or C1-6 alkyl;
each R6 is independently hydrogen or C1-6 alkyl; and
Z1 is selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy, C1-6 alkoxy, C3-10 cycloalkyl and C6-10 aryl; and
Z2 is selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy, C1-6 alkoxy, C3-10 cycloalkyl and C6-10 aryl.